Vynleads, Inc. reported zero revenue for both the fiscal years ended December 31, 2025, and December 31, 2024. The company incurred a net loss of $255,066 in 2025, a slight improvement from $261,192 in 2024. An accumulated deficit of $3,040,596 was reported as of December 31, 2025. The working capital deficit worsened to $(352,431) in 2025 from $(227,365) in 2024. Net cash used in operating activities was $(108,860) in 2025, an improvement from $(112,390) in 2024. The company's cash balance decreased to $44,628 at the end of 2025 from $68,988 at the end of 2024. Management requires approximately $5,500,000 in additional working capital over the next 12 months to fund business objectives, including platform development, product expansion, and marketing. The company is transitioning to an app-based subscription model for its Done With Diabetes platform, incorporating AI-enabled coaching and agentic workflows. A material weakness in internal control over financial reporting was identified due to limited personnel and lack of segregation of duties. The company's common stock trades on OTCQB under the symbol VYND, with a price of $0.43 as of March 24, 2026.